R. Scott Greer
Independent DirectorMr. R. Scott Greer, CPA, is the Founder of Numenor Ventures, LLC and has been its Managing Director since June 2002. He is Chairman of Vertero Therapeutics, Inc. since December 2025. Mr. Greer Co-founded Abgenix Inc. in 1996 and served as its Chief Executive Officer from June 1996 to May 2002 and its President from June 1996 to December 2000. He served as an Advisor of CombiMatrix Corporation since August 1, 2005. Mr. Greer served as Advisor of CombiMatrix at Acacia Research Corporation since August 1, 2005. He served as Vice President of Fidelity New York Municipal Trust - Fidelity New York Municipal Income Fund. He served as the Chairman and Chief Executive Officer of Izalex, Inc. From July 1994 to July 1996, he served as the Senior Vice President of Corporate Development at Cell Genesys Inc. He served as the Vice President of Corporate Development of Cell Genesys Inc. from April 1991 to July 1994 and served as its Chief Financial Officer from April 1991 to September 1993. From 1986 to 1991, Mr. Greer held various positions including the Director of Corporate Development at Genetics Institute, LLC. He has been the Chairman of Calimmune, Inc. since November 19, 2015. He has been the Chairman and Director of Acologix, Inc. since 2004 and 1999 respectively. He served as the Chairman of Ablexis, LLC since June 2010 until March 30, 2016. He served as the Chairman of Sirna Therapeutics Inc. (acquired by Merck) since March 1, 2006 and July 2003 respectively. Mr. Greer served as Chairman of Abgenix Inc. from May 2000 to 2006 and served as its Director since June 1996. He served as the Chairman of the board of LLS and Inogen, Inc. He has been an Independent Director of Nektar Therapeutics since February 01, 2010. He served as Director of Versartis, Inc. since December 09, 2014 until October 12, 2018. He was a Director of Sientra, Inc. since July 2014 until July 1, 2018. He served as an Independent Director of Inogen, Inc. since August 3, 2015 until May 24, 2021. He served as a Director of Ablexis, LLC since June 2010 until March 30, 2016. He served as Director of Inogen Inc. since April 2007, AnaptysBioScience Inc. since October 08, 2007, Illumina Inc. from May 2001 to April 12, 2005, Gilead Palo Alto, Inc., from September 2000 to April 2, 2004 and CV Therapeutics Inc. (acquired by Gilead, Inc.) from September 2000 to April 2, 2004. He served as a Director of StemCells Inc. since June 2010 until August 15, 2016. He served as a Director of Affymax, Inc., BaroNova Inc. and Izalex Inc. Mr. Greer served as Member of Advisory Board at Chimeros Inc. He served on the Board of the Santa Barbara Maritime Museum from 2003 to 2006. He served as a Director of Auspex, Inc. He served as a Director at Auspex Pharmaceuticals, Inc. (acquired by Teva Pharmaceuticals) since May 2014 until 2015. He previously served on the board of numerous private companies. Mr. Greer has experience and made direct investments in more than 20 healthcare, consumer product and technology companies. He has significant financial, business and management expertise, coupled with his extensive experience as a director of multiple life science companies. Prior to attending business school, Mr. Greer was an auditor with Coopers & Lybrand (now Pricewaterhouse Coopers, LLC). He is a Certified Public Accountant. He was honored as the Ernst & Young Entrepreneur of the Year (Northern California Life Sciences). Mr. Greer holds a M.B.A Degree from Harvard University and B.A Degree in Economics from Whitman College.
Positions
- Company NameNektar TherapeuticsStock CodeNKTRPositionIndependent DirectorColleagues
- HWHoward W. RobinCEO, President & Director
- RBRobert B. ChessIndependent Chairman of the Board
- JZJonathan ZalevskySenior VP and Chief Research & Development Officer
- LMLinda M. RubinsteinCFO and Principal Financial & Accounting Officer
- JBJason BarnardChief Accounting Officer
- EZElizabeth ZhangVP of Legal, Corporate Counsel & Secretary
- RARoy A. WhitfieldLead Independent Director
- DMDiana M. BrainardIndependent Director
